Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Brain Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | July 2016 |
| End Date: | June 2020 |
| Contact: | Mariza Daras, MD |
| Phone: | 212-610-0239 |
Pilot Study of 11C-Choline (11C-CH) PET in Assessing Post-treatment True Tumor Progression From Pseudo-progression in High-grade Gliomas
This is a pilot study. The purpose of this study is to test if an imaging tracer, not
approved by the FDA, called 11C-Choline (11C-CH) is useful for evaluating your type of
cancer. This tracer is used to perform PET scans. The researchers want to see if the 11C-CH
PET scan, using the study tracer 11C-CH, can improve upon the usual scans at diagnosing or
monitoring your type of cancer.
In patients with high-grade gliomas, changes on standard MRI of the brain may reflect true
tumor growth or inflammatory changes in response to treatment, called pseudo-progression. It
is important to distinguish true tumor growth from inflammation since inflammation indicates
the tumor is responding to treatment. With standard MRI, it is difficult to determine if
changes following treatment are due to tumor growth or inflammation early on. Researchers
hope to learn if the investigational tracer, 11C-CH, will be able to distinguish true tumor
growth from inflammation more accurately than standard MRI or 18F-FDG PET scans.
approved by the FDA, called 11C-Choline (11C-CH) is useful for evaluating your type of
cancer. This tracer is used to perform PET scans. The researchers want to see if the 11C-CH
PET scan, using the study tracer 11C-CH, can improve upon the usual scans at diagnosing or
monitoring your type of cancer.
In patients with high-grade gliomas, changes on standard MRI of the brain may reflect true
tumor growth or inflammatory changes in response to treatment, called pseudo-progression. It
is important to distinguish true tumor growth from inflammation since inflammation indicates
the tumor is responding to treatment. With standard MRI, it is difficult to determine if
changes following treatment are due to tumor growth or inflammation early on. Researchers
hope to learn if the investigational tracer, 11C-CH, will be able to distinguish true tumor
growth from inflammation more accurately than standard MRI or 18F-FDG PET scans.
Inclusion Criteria:
- Age ≥ 18 years
- Patient is able to provide written informed consent prior to study registration
- Histologically-confirmed high-grade glioma
- Completion of treatment with standard radiation (with or without concurrent therapy).
- Standard gadolinium-enhanced MRI changes that are considered indeterminate for tumor
progression vs. treatment-related changes by the neuroradiologist or clinician within
24 weeks of completion of radiation.
Exclusion Criteria:
- Inability to undergo or cooperate with an MRI or PET scan (e.g., claustrophobia, metal
implant)
- Renal insufficiency with recent (<3 month old) creatinine > 2.0 mg/dL
- Pregnant or nursing female
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-610-0239
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
